Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $10.1 million.

  • Voyager Therapeutics' Gains from Investment Securities rose 1359.06% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 1359.06%. This contributed to the annual value of $8.8 million for FY2024, which is 1851.77% up from last year.
  • Voyager Therapeutics' Gains from Investment Securities amounted to $10.1 million in Q3 2025, which was up 1359.06% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Gains from Investment Securities ranged from a high of $10.5 million in Q1 2025 and a low of -$2.8 million during Q4 2022
  • Moreover, its 5-year median value for Gains from Investment Securities was $6.8 million (2022), whereas its average is $5.8 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 361911.76% in 2021, then surged by 9876.98% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Gains from Investment Securities stood at -$2.5 million in 2021, then decreased by 12.5% to -$2.8 million in 2022, then skyrocketed by 98.77% to -$35000.0 in 2023, then rose by 8.57% to -$32000.0 in 2024, then skyrocketed by 31590.6% to $10.1 million in 2025.
  • Its last three reported values are $10.1 million in Q3 2025, $10.3 million for Q2 2025, and $10.5 million during Q1 2025.